Netherlands · Biotechnology startup
Netherlands · LUMICKS
LUMICKS provides single-molecule analysis technologies for cancer research and immunotherapy.
Funding reportedLast round: Series D
What company datasets say LUMICKS raised
Funding, as reported
Reported in all77.8Min the source's currency
Rounds5
Last roundSeries D
Last round dateApr 2021
Investors listed11
Founders and team
From LUMICKS's own website: 3 on the team.
- Hugo de WitChief Executive Officer
- Edmee VerhulpChief Financial Officer
- Hannah van DrunenHR Director
Biotechnology in Netherlands
Startups like it
Is this your company?
Add your raise, your deck and your story, and put LUMICKS in front of investors. Or tell us what we have wrong.